HR Execs on the Move

Heron Therapeutics

www.appharma.com

 
Heron Therapeutics is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by extending the duration of action. The Company's lead product, SUSTOL™ (formerly APF530), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. Heron Therapeutics received a Complete Response Letter to its SUSTOL New Drug Application (NDA) and is targeting a resubmission of the NDA to the U.S. Food and Drug Administration during the fourth quarter of 2014. Heron Therapeutics' core Biochronomer technology, on which ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.appharma.com
  • 123 Saginaw Dr
    Redwood City, CA USA 94063
  • Phone: 650.366.2626

Executives

Name Title Contact Details

Similar Companies

Vascular Therapies

Vascular Therapies, Inc., a privately-held late-stage biopharmaceutical company, is developing the Sirolimus-eluting collagen implant for local, perivascular drug delivery.

Inotiv

Inotiv: (bio)analytical, in vivo, toxicology and molecular pathology services for preclinical drug metabolism in drug development.

Learn to Live CBT

Learn to Live offers online therapy programs for Stress, Depression and Social Anxiety based on the proven principles of Cognitive Behavioral Therapy (CBT).

The Portland Clinic

At The Portland Clinic, we’ve been treating the people in our community with trust, kindness and understanding for nearly 100 years. For us, that means asking good questions and paying close attention to your answers. Working hard to find out where you...

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is a clinical stage, Nasdaq listed (ticker ARWR) company developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, our therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Our RNAi-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. Our Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. The TRiM platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing and reduced costs; multiple routes of administration; and potential for improved safety. Our employees are nimble, science-driven, and innovative professionals. A career at Arrowhead offers the opportunity to collaborate with top notch scientists to rapidly discover and develop RNAi-based therapeutics to add to our growing pipeline. Research and development activities are located in Madison, WI. Our R&D group includes fully-integrated capabilities for chemistry, biology, and toxicology. Madison is an exciting and sophisticated city that includes state government, the flagship campus of the University of Wisconsin, and major research organizations. Our HQ, clinical and regulatory operations are located in Pasadena, CA. Just north of Los Angeles and resting in the foothills of the San Gabriel Mountains, Pasadena is known for its natural scenic beauty, vibrant cultural and academic environment and rich architectural setting.